Rifampin in treatment of advanced pulmonary tuberculosis. Report of a VA cooperative pilot study.
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced; D000469:Alkaline Phosphatase / Q000097:blood; D000995:Antitubercular Agents / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D004352:Drug Resistance, Microbial; D004802:Eosinophilia / Q000139:chemically induced; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000009:adverse effects / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014527:Uric Acid / Q000097:blood
D000995:Antitubercular Agents; D014527:Uric Acid; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D001663:Bilirubin; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin